Clinical trial NCT05621031: Effects of Whole Body Vibration in Parkinson's Disease Symptoms
Official title: Effects of Whole Body Vibration in Parkinson's Disease Symptoms
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Parkinson Disease
Keywords: parkinson disease,
whole body vibration
rigidity
Lead sponsor: University of Seville
Sponsor class: OTHER
Collaborators: name: Asociación de Enfermos de Parkinson de Sevilla
First posted: 2022-11-17
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to know the effects of an intervention in Parkinson's disease symptoms. The main question it aims to answer are:

* Is whole body vibration able to reduce rigidity in Parkinson's participants?
* Can whole body vibration modify gait abilities and other Parkinson's symptoms? Participants (subjects with Parkinson's disease) will do habitual therapy treatment. Experimental group will also carry out whole body vibration sessions and control group will do placebo whole body vibration sessions.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of Parkinson Disease, in phase I and II according to Hoehn \& Yahr phases.
* Able to maintain independently standing position.
* Able to understand instructions and score \>24 in Minimental Test.

Exclusion Criteria:

* Changes in pharmacological treatment for PD symptoms during the study.
* Recent injuries in the last 12 weeks in lower limbs or trunk.
* Other neurological conditions not related to Parkinsonism.

Primary outcomes:
measure: Change from baseline muscle tone at 9 weeks
timeFrame: Week 9
measure: Change from baseline muscle stiffness at 9 weeks
timeFrame: Week 9
measure: Change from baseline muscle elasticity at 9 weeks
timeFrame: Week 9
measure: Change from week 9 muscle tone at 22 weeks (follow up period)
timeFrame: Week 22
measure: Change from week 9 muscle stiffness at 22 weeks (follow up period)
timeFrame: Week 22
measure: Change from week 9 muscle elasticity at 22 weeks (follow up period)
timeFrame: Week 22
measure: Changes from baseline gait functionality at 9 weeks
timeFrame: Week 9
measure: Changes from week 9 gait functionality at 22 weeks (follow up period)
timeFrame: Week 22
Secondary outcomes:
measure: Changes from baseline thoracic kyphosis at 9 weeks
timeFrame: Week 9
measure: Changes from week 9 thoracic kyphosis at 22 weeks (follow up period)
timeFrame: Week 22
measure: Changes from baseline aspects of quality of life at 9 weeks
timeFrame: Week 9
measure: Changes from week 9 aspects of quality of life at 22 weeks (follow up period)
timeFrame: Week 22
measure: Changes from baseline freezing of gait at 9 weeks
timeFrame: Week 9
measure: Changes from week 9 freezing of gait at 22 weeks (follow up period)
timeFrame: Week 22
measure: Changes from baseline reactive balance at 9 weeks
timeFrame: Week 9
measure: Changes from week 9 reactive balance at 22 weeks
timeFrame: Week 22
Other outcomes:
measure: Age
timeFrame: Baseline
measure: Height
timeFrame: Baseline
measure: Weight
timeFrame: Baseline
measure: Time since Parkinson disease diagnosis
timeFrame: Baseline
Locations:
city: Sevilla
country: Spain
facility: Asociación de Enfermos de Parkinson de Sevilla
Study officials:
References: